| name | endo-srl-primary-unresectable-surgery |
| description | Recommends initiating a somatostatin receptor ligand (SRL) as primary medical therapy for acromegaly when curative surgery is not possible. Consider this approach in patients with extensive cavernous sinus invasion, absence of chiasmal compression, or those deemed poor surgical candidates. |
SRL as primary therapy when surgery not curative
STEP 1 — Gather Information
Confirm biochemical diagnosis of acromegaly (elevated IGF-1, lack of GH suppression). Obtain pituitary MRI to assess tumor size, cavernous sinus invasion, and relationship to optic chiasm. Evaluate surgical candidacy (comorbidities, patient preference, anesthetic risk). Record baseline IGF-1, GH, visual field, and surgical risk assessment.
STEP 2 — Rule In / Rule Out
If MRI shows resectable tumor with low morbidity and the patient is a suitable surgical candidate, proceed to transsphenoidal surgery (outside this skill); otherwise, indicate that curative surgery is not feasible and advance to step 3.
STEP 3 — Classify or Stratify
Classify the patient as having extensive cavernous sinus invasion (MRI grade ≥2), lack of chiasmal compression, or being a poor surgical candidate (ASA ≥3, uncontrolled comorbidities, or patient refusal). This classification confirms eligibility for primary SRL therapy.
STEP 4 — Decide
Initiate long-acting SRL therapy (octreotide LAR 20 mg IM monthly or lanreotide autogel 90 mg SC monthly). Schedule IGF-1 and GH assessment 12 weeks after start to evaluate biochemical response.
Clinical Guardrails / Mimics / Pitfalls
Do not use SRL as primary therapy when there is compressive optic chiasm syndrome requiring urgent decompression. Avoid SRL monotherapy if the patient is a good surgical candidate with low operative risk. Monitor for SRL‑related side effects (gallstones, gastrointestinal disturbances, glucose intolerance) and adjust dose or add pegvisomant if IGF-1 remains elevated after 3‑6 months.
Concrete Clinical Example
A 48‑year‑old woman with acromegaly presents with headaches and acral enlargement. IGF-1 is 2.5 × ULN, GH fails to suppress. MRI shows a 12 mm macroadenoma with bilateral cavernous sinus invasion but no optic chiasm contact. She has poorly controlled type 2 diabetes and declines surgery. Start octreotide LAR 20 mg IM monthly; re‑check IGF-1 at 12 weeks.
Source: Acromegaly: An Endocrine Society Clinical Practice Guideline, Endocrine Society, 2014, DOI:10.1210/jc.2014-2700
